| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
| filingDate |
2018-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_837c2b09abf60059073bddc7d343a551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4475696dfd508658fed4bc701429d6c3 |
| publicationDate |
2019-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201904584-A |
| titleOfInvention |
Method for reducing or preventing cardiovascular events in patients with type 2 diabetes |
| abstract |
The present invention relates to a method for reducing, preventing, or slowing the progression of cardiovascular risk factors and / or cardiovascular disease, which comprises administering canglitazone. |
| priorityDate |
2017-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |